TheEdgeResearch
Home / Stocks / VPAHF

Volpara Health Technologies Limited (VPAHF)

OTC Healthcare Medical - Healthcare Information Services
$0.74 ▲ +36.63%
Market Cap
$188.2M
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
1.67
52-Wk Range
0.41-0.8946
CEO
Teri Jo Thomas
Country
NZ
Currency
USD

Volpara Health Technologies Limited operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Wellington, NZ. The stock last traded at $0.74, up 36.63% on the session, giving a market capitalisation of $188.2M. On trailing twelve-month figures it carries a trailing P/E of -28.94, a net margin of -28.0%. Its beta of 1.67 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-28.94
Price / Sales
8.18
Price / Book
5.54
EV / EBITDA
-37.79
Gross margin
92.5%
Operating margin
-31.4%
Net margin
-28.0%
Return on equity
—
Debt / equity
0.04
Current ratio
0.99
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
156
IPO date
2018-01-16
Headquarters
Wellington, NZ
About Volpara Health Technologies Limited

Established in 2009 and headquartered in Wellington, New Zealand, Volpara Health Technologies Limited specializes in developing advanced software solutions, primarily for breast imaging analytics. The company's diverse product portfolio aims to enhance and optimize various aspects of cancer screening. Key offerings include Volpara Analytics, which streamlines breast cancer screening operations, and Volpara Live, providing instant, patient-specific feedback on image quality. For lung cancer screening, Volpara Lung offers patient management software to streamline workflows. The Volpara Patient Hub is a versatile platform for customizable mammography reporting and patient communications. Integrating with this, Volpara Risk utilizes TC8 to compute patients' breast cancer risk, while Volpara Risk Pathways is a dedicated program for identifying and managing high-risk screening patients. Volpara Scorecard delivers crucial insights into breast density and risk, facilitating better clinical decisions and earlier detection. Many of these products are powered by Volpara Science, an underlying AI-based software. The company also offers specialized clinical functions such as TruDensity for breast density assessment, TruPGMI which leverages artificial intelligence to objectively evaluate patient positioning and image clarity, TruPressure to ensure optimal compression for quality images, minimal radiation, and comfort, and TruRadDose, analyzing radiation exposure based on breast density. Volpara Health Technologies operates internationally across North America, the Asia Pacific, Europe, the Middle East, and Africa, and maintains a strategic alliance with RevealDx.

Comparable companies

Volpara Health Technologies Limited is most often compared with the following Healthcare names:

ADOCYAMGXFBRNHFDLHTFEKDHFFPHAFNNGRFPLNHFRECEFSMDCF
More research on VPAHF
VPAHF technical analysis VPAHF TheEdge Score Compare against peers
Open full interactive analysis & DCF →